SCHEMBL6411387

SCHEMBL6411387

COCCNC(=O)C1c2ccccc2C(=O)N(CCC(=O)NCCc2cccc(OC)c2)C1c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
KDM4E B2RXH2 1/20 0.54
MAPT P10636 1/20 0.54
HTT P42858 1/20 0.54
TP53 P04637 2/20 0.49
MDM2 Q00987 1/20 0.49
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 3/20 0.46
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 1/20 0.43
IDO1 P14902 1/20 0.42
GLA P06280 1/20 0.42
CASP1 P29466 1/20 0.42
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6416210 0.92 HSD17B10 (0.44) ALDH1A1KDM4EMAPTHTTTSHR
SCHEMBL6411391 0.85 ALDH1A1 (0.45) ALDH1A1KDM4EMAPTHTTTP53
SCHEMBL6414939 0.84 ALDH1A1 (0.74) ALDH1A1KDM4EMAPTHTTTP53
SCHEMBL6412385 0.84 ALDH1A1 (0.74) ALDH1A1KDM4EMAPTHTTTP53
SCHEMBL6417311 0.83 ALDH1A1 (0.66) ALDH1A1KDM4EMAPTHTTTP53
SCHEMBL6418778 0.82 ALDH1A1 (0.61) ALDH1A1KDM4EMAPTHTTTP53
SCHEMBL6411589 0.82 MDM2 (0.68) ALDH1A1KDM4EMAPTHTTTP53
SCHEMBL2938982 0.81 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTHTTTP53
SCHEMBL6413224 0.81 ALDH1A1 (0.60) ALDH1A1KDM4EMAPTHTTTP53
SCHEMBL6419057 0.81 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTHTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD ALDH1A1 1368/4885KDM4E 2355/4885MAPT 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.